Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapi… Read more
Kura Oncology Inc (KURA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.673x
Based on the latest financial reports, Kura Oncology Inc (KURA) has a cash flow conversion efficiency ratio of 0.673x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($117.27 Million) by net assets ($174.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kura Oncology Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Kura Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kura Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kura Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sunway Co Ltd
SHG:603333
|
-0.019x |
|
PT Indo Tambangraya Megah Tbk
F:3IB
|
-0.015x |
|
SÜSS MicroTec SE
PINK:SESMF
|
0.019x |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
-0.055x |
|
Lonking Holdings Limited
F:C9IB
|
0.042x |
|
Shenzhen Prince New Materials Co Ltd
SHE:002735
|
0.019x |
|
MultiChoice Group Limited
F:30R
|
1.014x |
|
ARDAGH METAL PAC.DL-0001
F:7JZ
|
N/A |
Annual Cash Flow Conversion Efficiency for Kura Oncology Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Kura Oncology Inc from 2009 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $174.13 Million | $-64.06 Million | -0.368x | -213.29% |
| 2024-12-31 | $413.64 Million | $134.32 Million | 0.325x | +203.35% |
| 2023-12-31 | $397.27 Million | $-124.82 Million | -0.314x | -19.98% |
| 2022-12-31 | $420.28 Million | $-110.06 Million | -0.262x | -26.90% |
| 2021-12-31 | $506.61 Million | $-104.55 Million | -0.206x | -80.55% |
| 2020-12-31 | $610.90 Million | $-69.83 Million | -0.114x | +54.33% |
| 2019-12-31 | $218.78 Million | $-54.76 Million | -0.250x | +17.18% |
| 2018-12-31 | $160.99 Million | $-48.66 Million | -0.302x | +15.13% |
| 2017-12-31 | $79.86 Million | $-28.44 Million | -0.356x | +20.10% |
| 2016-12-31 | $56.88 Million | $-25.35 Million | -0.446x | -104.14% |
| 2015-12-31 | $82.10 Million | $-17.93 Million | -0.218x | -29526.93% |
| 2014-12-31 | $-3.43 Million | $-2.55K | 0.001x | -99.62% |
| 2013-12-31 | $-123.96K | $-24.42K | 0.197x | -17.18% |
| 2012-12-31 | $-95.35K | $-22.68K | 0.238x | -15.92% |
| 2011-12-31 | $-68.03K | $-19.24K | 0.283x | -39.75% |
| 2010-12-31 | $-40.99K | $-19.24K | 0.469x | -59.14% |
| 2009-12-31 | $-18.60K | $-21.37K | 1.149x | -- |